BiotechTube
SunRock Biopharma

SunRock Biopharma

Barcelona, Spain· Est.
sunrockbiopharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

SunRock Biopharma is a private, preclinical-stage biotech focused on developing novel antibodies for oncology, with a core expertise in targeting chemokine receptor CCR9 and the HER3 (ERBB3) pathway. The company has established a pipeline of mono- and bi-specific antibodies, with several HER3-targeting assets already licensed to Debiopharm, providing non-dilutive funding and validation. SunRock's strategy centers on addressing tumor metastasis and therapy resistance, positioning it in the competitive but high-value oncology biologics space.

Oncology

Technology Platform

Antibody engineering for improved affinity and novel mechanisms of action, focusing on monoclonal and bispecific antibodies.

Opportunities

The high unmet need in metastatic and treatment-resistant cancers presents a large addressable market.
The novel CCR9 target offers a potential first-in-class opportunity in a less crowded space than HER3.
The partnership with Debiopharm provides validation, non-dilutive funding, and a clear development path for a significant portion of the pipeline.

Risk Factors

High preclinical scientific risk that novel mechanisms may not translate to human efficacy.
Intense competition in the oncology antibody space, particularly around the HER3 target.
Dependence on future financing or partnership deals to advance internal programs beyond preclinical stages.

Competitive Landscape

The HER3 competitive landscape is crowded with candidates from large pharma and biotech, though no therapy is yet approved. The CCR9 space is less developed, offering a niche opportunity. SunRock's differentiation lies in its antibody engineering for improved affinity and novel mechanisms aimed at overcoming resistance.

More companies in Oncology (General) →More companies in Spain →